WEDGE(000534)2025-03-06 12:05Financial Performance - The company's operating revenue for 2024 reached ¥1,078,865,064.75, an increase of 9.93% compared to ¥981,439,362.70 in 2023[18]. - Net profit attributable to shareholders for 2024 was ¥192,740,650.65, reflecting a growth of 9.17% from ¥176,554,971.16 in 2023[18]. - The net profit after deducting non-recurring gains and losses was ¥160,423,440.22, a significant increase of 54.12% compared to ¥104,087,060.80 in 2023[18]. - The company's cash flow from operating activities improved to ¥114,256,746.75, up 20.60% from ¥94,738,878.02 in 2023[18]. - Basic earnings per share for 2024 were ¥0.3932, representing a 10.02% increase from ¥0.3574 in 2023[18]. - Total assets at the end of 2024 amounted to ¥3,970,281,336.21, a 27.24% increase from ¥3,120,279,712.38 at the end of 2023[18]. - Total revenue for 2024 reached ¥1,078,865,064.75, representing a year-on-year increase of 9.93% compared to ¥981,439,362.70 in 2023[48]. - The net profit attributable to the parent company was 192.74 million yuan, an increase of 9.17% compared to the previous year[37]. Business Focus and Strategy - The company has shifted its main business focus from power generation to the research, manufacturing, and sales of high-temperature alloys and related technical services since 2018[16]. - The high-temperature alloy business is positioned to meet the substantial market demand, particularly in aerospace and energy sectors, with the company being one of the few capable of full-process development in this area[28]. - The company has established a strong market presence in the micro-ecological live bacteria product sector, with significant growth in demand driven by increased health awareness among consumers[27]. - The company is focused on expanding its capabilities in high-end manufacturing, particularly in aerospace and energy sectors, to maintain its competitive edge[60]. - The company is leveraging stable cash flow from its microbiological preparation business to support the accelerated development of its high-temperature alloy business, which is currently in the industrialization phase[83]. Research and Development - The company has established a comprehensive R&D and testing system, achieving multiple key technological breakthroughs and obtaining several patents in high-temperature alloy materials[36]. - The company has successfully developed and delivered high-temperature alloy powder components, entering the mass production phase[36]. - The company aims to establish a strain resource library, accumulating approximately 10 new strains annually, enhancing strain research capabilities and external collaboration evaluation[59]. - The company is developing new probiotic products, with plans to apply for 1-2 new drug approvals[59]. - The company has initiated clinical research on the mechanism and effects of its products, expanding product indications to increase sales[59]. - The company has made breakthroughs in the precision casting and heat treatment of second-generation single crystal high-temperature alloy turbine blades, establishing a strong technical foundation for future third-generation blade development[60]. Market and Sales - The pharmaceutical manufacturing segment generated ¥804,792,682.67, accounting for 74.60% of total revenue, with a growth of 14.87% from ¥700,617,023.47 in the previous year[48]. - The "Dingjunsheng" product line saw a revenue increase of 36.81%, reaching ¥267,093,057.48, up from ¥195,229,637.62 in 2023[48]. - The company has built a nationwide multi-channel marketing system, collaborating with over 3,000 hospitals and more than 100,000 pharmacies[33]. - The company has integrated its pharmaceutical sector across northern and southern markets, implementing a unified management model for clinical, academic, and commercial operations[42]. Shareholder and Governance - The company reported a cash dividend of 0.5 yuan per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The company plans to distribute dividends over the next three years (2024-2026) as part of its profit distribution plan, which was approved at the 2023 annual general meeting with a voting approval rate of 48.57%[97]. - The company has a structured remuneration decision-making process involving the remuneration committee and shareholder approval[110]. - The company actively protects the interests of shareholders, particularly minority shareholders, by enhancing internal governance and providing online voting for major decisions[160]. Financial Management - The company has committed to repurchase shares with a total fund of no less than CNY 250 million and no more than CNY 500 million, with a maximum repurchase price of CNY 15.95 per share[198]. - The company has completed a share buyback plan with an investment amount between 80 million and 160 million CNY[166]. - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period[167]. - The company has not reported any overdue or unrecovered amounts from entrusted financial management[195]. Compliance and Internal Control - The company maintained effective internal control over financial reporting as of December 31, 2024, with no significant deficiencies identified[156]. - The company has established a comprehensive internal control system to ensure compliance and enhance operational efficiency[152]. - There were no significant environmental penalties or issues reported during the reporting period[158]. - The company has not encountered any situations where expected recoveries of principal from entrusted financial management are at risk[195]. Future Plans - The company plans to hold a strategic planning seminar in 2025 to outline its five-year objectives and implementation paths[81]. - The company aims to enhance its R&D capabilities by collaborating with Guangdong Pharmaceutical University and other institutions[81]. - The company aims to establish a commercial production line for third-generation single crystal high-temperature alloys within five years, enhancing its competitive edge in the market[61].